Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 800-807

  Palumbo, Antonio ^a   Gay, Francesca ^a   Falco, Patrizia ^a   Crippa, Claudia ^a   Montefusco, Vittorio ^a   Patriarca, Francesca ^a   Rossini, Fausto ^a   Caltagirone, Simona ^a   Benevolo, Giulia ^a   Pescosta, Norbert ^a   Guglielmelli, Tommasina ^a   Bringhen, Sara ^a   Offidani, Massimo ^a   Giuliani, Nicola ^a   Petrucci, Maria Teresa ^a   Musto, Pellegrino ^a   Liberati, Anna Marina ^a   Rossi, Giuseppe ^a   Corradini, Paolo ^a   Boccadoro, Mario ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; MACROGOL DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HEART INFARCTION; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INFECTION; INTESTINE INFARCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; STEM CELL TRANSPLANTATION; TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CHEMOTHERAPY, ADJUVANT; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOADJUVANT THERAPY; POLYETHYLENE GLYCOLS; PREDNISONE; PROTEASE INHIBITORS; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 77649215631     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.7561     Document Type: Article

References (37)

1. American Cancer Society: Cancer Facts and Figures 2005. Atlanta, GA, American Cancer Society, 2005
2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488, 2005
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
4. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
5. Harousseau JL, Mathiot C, Attal M, et al: Velcade/dexamethasone (VEL/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: Updated results of the IFM 2005/01 trial. Blood 110:450, 2007 (suppl; abstr)
6. Orlowski RZ, Nagler A, Sonneveld P, et al: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed of refractory multiple myeloma. J Clin Oncol 25:3892-3901, 2007
7. Popat R, Oakervee HE, Hallam S, et al: Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: Updated results after long-term follow-up. Br J Haematol 141:512-516, 2008 (Pubitemid 351550543)
8. Palumbo A, Facon T, Sonneveld P, et al: Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111:3968-3977, 2008
9. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142, 2007 (Pubitemid 350146108)
10. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132, 2007 (Pubitemid 350146107)
11. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006
12. Spencer A, Prince HM, Roberts A, et al: Thalidomide improves survival when used following ASCT. Haematologica 92:41, 2007 (suppl s2; abstr S7b.5)
13. Ludwig H, Hajek R, Tóthová E, et al: Thalidomide- dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113:3435-3442, 2009
14. Morgan GJ, Jackson GH, Davies FE, et al: Maintenance thalidomide may improve progression free but not overall survival: Results from the Myeloma IX Maintenance Randomisation. Blood 112:656, 2008 (suppl; abstr)
15. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006
16. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120, 2006
17. National Cancer Institute: Common Terminology Criteria for Adverse Events, v3.0. http://ctep.cancer .gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-v30
18. Ahmann GJ, Jalal SM, Juneau AL, et al: A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gamopathies. Cancer Genet Cytogenet 101:7-11, 1998
19. Fonseca R, Barlogie B, Bataille R, et al: Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 64:1546-1558, 2004 (Pubitemid 38235629)
20. Fleming TR: One-sample multiple testing procedures for phase II clinical trials. Biometrics 38:143-151, 1982
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. San-Miguel J, Harousseau JL, Joshua D, et al: Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 26:2761-2766, 2008
23. Macro M, Divine M, Uzunhan Y, et al: Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): A randomized trial. Blood 108:57, 2006 (suppl; abstr)
24. Lacy MQ, Gertz MA, Dispenzieri A, et al: Long-term results of responses to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82:1179-1184, 2007
25. Harousseau JL, Attal M, Leleu X, et al: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 91:1498-1505, 2006 (Pubitemid 44736116)
26. Cavo M, Tacchetti P, Patriarca F, et al: Superior complete response rate and progression-free survival after autologous transplantation with upfront Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood 112:158, 2008 (suppl; abstr)
27. Richardson P, Lonial S, Jakubowiak A, et al: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: Encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood 112:92, 2008 (suppl; abstr)
28. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831, 2006
29. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370:1209-1218, 2007
30. San Miguel JF, Schlag R, Khuageva N, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
31. Palumbo A, Bringhen S, Petrucci MT, et al: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 104:3052-3057, 2004
32. Ladetto M, Pagliano G, Ferrero S, et al: Major shrinking of residual tumor cell burden and achievement of molecular remissions in myeloma patients undergoing post-transplant consolidation with bortezomib, thalidomide and dexamethasone: A qualitative and quantitative PCR study. Blood 112:3683, 2008 (suppl; abstr)
33. Bensinger W, Jagannath S, Vescio R, et al: A phase II study of bortezomib (Velcade), cyclophosphamide (Cytoxan), thalidomide (Thalomid) and dexamethasone as first-line therapy for multiple myeloma. Blood 112:94, 2008 (suppl; abstr)
34. Mateos MV, Hernández JM, Hernández MT, et al: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 108:2165-2172, 2006
35. Palumbo A, Falco P, Corradini P, et al: Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 25: 4459-4465, 2007
36. Rajkumar SV, Jacobus S, Callander N, et al: Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi [sic]. J Clin Oncol 26:455s, 2008 (suppl 15S; abstr 8504)
37. Palumbo A, Bringhen S, Rossi D, et al: A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 112:652, 2008 (suppl; abstr)